Search the Newsreel

Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours

Daré Bioscience reported a narrowed Q2 2026 net loss of $3.0 million, down from $4.0 million year-over-year, with revenue reaching $0.2 million. The company's stock initially fell but then surged 21.2% after hours, as investors reacted positively to progress in commercialization with new product …

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

Daré Bioscience launches Flora Sync, its first directly commercialized product

Daré Bioscience (NASDAQ: DARE) reported Q2 2026 revenue of $0.19 million, a net loss of $3.0 million, and $12.6 million in cash and equivalents. The company announced the launch of Flora Sync LF5, its first directly commercialized product, which began generating revenue in July …

Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances

Daré Bioscience reported its Q2 2026 financial results, highlighting significant progress in its multi-product women's health strategy. The company launched Flora Sync LF5 and is preparing for national dispensing of DARE to PLAY Sildenafil Cream, expecting initial revenue in Q3 2026. Daré also provided …

Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary

Dare Bioscience, Inc. reported its 2026 quarterly results, with revenue of $187.55K and a net loss of ($2.98M), which is an improvement from the prior year's loss. The company saw revenue growth due to Gates Foundation agreements and the launch of new products and …

Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates

Dare Bioscience Inc (DARE) has an earnings forecast score of 8.00, ranking 58th in the Pharmaceuticals industry, with a consensus analyst price target of $11.50, suggesting a significant upside. Three analysts have rated the stock as a "Buy" with a target price increase of …

Dare Bioscience (DARE.US) will release its earnings report after market close on August 13.

Dare Bioscience (DARE.US) is scheduled to release its earnings report on August 13, after the market closes. This announcement provides key information for investors and stakeholders anticipating the company's financial performance.

Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Dare Bioscience Inc (DARE), focusing on its support, resistance, and various technical indicators and moving averages. As of the analysis, DARE's stock price momentum score is 6.20, trading between a resistance level of $1.94 and a support …

Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026

Daré Bioscience, Inc. (NASDAQ: DARE) will host a conference call and webcast on Thursday, August 13, 2026, at 4:30 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2026, and provide a company update. Investors can access the …

Daré Bioscience, Inc. (DARE) Stock Price, News, Quote & History

This article provides detailed financial information for Daré Bioscience, Inc. (DARE), including its current stock price, historical data, analyst ratings, and company overview. It highlights the company's focus on developing therapies for women's health and outlines its various product candidates in different stages of …

Daré Bioscience sets Aug. 13 update on women's health work

Daré Bioscience (NASDAQ: DARE) will host a conference call and webcast on Thursday, August 13, 2026, at 4:30 PM Eastern Time. The call will cover the company's second-quarter 2026 financial results and provide a general corporate update. Investors can access the event via phone …

Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx

Daré Bioscience has partnered with MyMenopauseRx to expand access to DARE to PLAY™ Sildenafil Cream and specialized menopause care. This collaboration aims to build a comprehensive women's health ecosystem by offering women more pathways to expert care, including lifestyle counseling and hormonal treatments. The …

Dare Bioscience Inc (DARE) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Dare Bioscience Inc (DARE), noting its current valuation score of 8.43, ranking 57th in the Pharmaceuticals industry. The report highlights its P/E ratio of -1.41, which is significantly below its recent high and above its recent low. …

Dare Bioscience, Inc. Revenue Breakdown – NASDAQ:DARE

Dare Bioscience, Inc. (NASDAQ: DARE) generated $1.03 million USD in revenue last year, primarily from its Women's Health segment. This marks a significant increase from the previous year's revenue of $9.78 thousand USD. The United States was the greatest contributor to this revenue, accounting …

Dare Bioscience Inc (DARE) Institutional Confidence

The article analyzes the institutional confidence in Dare Bioscience Inc (DARE), noting its current institutional shareholding score is 3.00, placing it 92nd out of 155 in the Pharmaceuticals industry. Institutional shareholding has increased to 8.57% quarter-over-quarter, with James Simons identified as the largest institutional …

Dare Bioscience Inc (DARE) Financials

This article provides a detailed financial overview of Dare Bioscience Inc (DARE), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators like EPS, revenue, net profit, and various margins, alongside the company's latest earnings date and analyst ratings. …

Dare Slides on MyMenopauseRx Hookup

Daré Bioscience, Inc. (NASDAQ: DARE) has partnered with MyMenopauseRx, a telehealth platform specializing in menopause care, to enhance access to dedicated menopause treatment for users of DARE to PLAY™ Sildenafil Cream. This collaboration expands Daré's commercial strategy by offering women comprehensive menopause support, including …

Daré Bioscience Launches MyMenopauseRx Telehealth Collaboration for DARE to PLAY™ Menopause Care

Daré Bioscience has partnered with MyMenopauseRx to launch a telehealth collaboration for DARE to PLAY™ Sildenafil Cream, aiming to improve access to specialized menopause care. This initiative will offer women personalized care, including lifestyle counseling and hormonal treatments, alongside Daré's product, expanding its commercial …

Women Exploring DARE to PLAY Can Now Reach Menopause Specialists

Daré Bioscience has partnered with MyMenopauseRx, a telehealth platform specializing in menopause care, to expand access to specialists for women considering DARE to PLAY™ Sildenafil Cream. This collaboration aims to build a comprehensive women's health ecosystem by connecting innovative products with education, clinical expertise, …

Dare Bioscience Inc (DARE) Income Statement

This article provides the quarterly and annual income statements for Dare Bioscience Inc (DARE), offering detailed financial data such as total revenue, operating expenses, net income, and earnings per share. It also includes frequently asked questions to help users interpret the financial information and …

Dare Bioscience Market Sentiment

This article provides an overview of market sentiment for Dare Bioscience (DARE), including analyst consensus, short interest, and recent analyst actions. Four analysts have a "Buy" consensus with an average price target of $9, representing a significant upside. The short interest currently stands at …

Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic?

Daré Bioscience, Inc., a biopharmaceutical company with a US$29m market cap, is reportedly nearing profitability, with analysts predicting breakeven in 2027 and a profit of US$1.3m in 2028. This growth requires an extremely buoyant 66% year-on-year increase. However, the company also carries a significant …

Daré Bioscience launches virtual bus tour webinars to share growth plans and engage investors

Daré Bioscience, a biotech company focused on women's health, has initiated a virtual bus tour webinar series to engage investors. Hosted by CEO Sabrina Martucci Johnson, these webinars will provide updates on the company's commercial strategy, product portfolio, and growth opportunities. The series also …

Daré Bioscience Launches “Across the U.S.” Virtual Bus Tour Webinar Series for Investors

Daré Bioscience (NASDAQ: DARE) has announced a "Across the U.S." Virtual Bus Tour Webinar Series for investors, aimed at providing direct access to company leadership and insights into its women's health portfolio and commercial strategy. Hosted by CEO Sabrina Martucci Johnson, the series will …

Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities

Daré Bioscience, Inc. announced the launch of its "Across the U.S." Virtual Bus Tour Webinar Series, a multi-event investor engagement initiative. The series, hosted by CEO Sabrina Martucci Johnson, will provide updates on the company's commercial strategy, product portfolio, growth opportunities, and a Regulation …

Dare Bioscience Received Notice of Delisting

Dare Bioscience (DARE) has received a notice from Nasdaq regarding its non-compliance with Listing Rule 5550(b) because its stockholders' equity is below $2.5 million. The company plans to request a hearing to appeal the delisting notification, which will temporarily stay any suspension or delisting …